Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.62 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.61 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.54 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 5/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24484211 | 0.83 | PDE7A (0.43) | PDK2PDK4PDK1PDK3CNR1 | |
| SCHEMBL2269040 | 0.78 | PDK2 (0.61) | PDK2PDK4PDK1PDK3PDE7A | |
| SCHEMBL10828239 | 0.78 | PDK2 (0.61) | PDK2PDK4PDK1PDK3CNR1 | |
| SCHEMBL31117008 | 0.78 | PDK2 (0.61) | PDK2PDK4PDK1PDK3CNR1 | |
| SCHEMBL3138211 | 0.78 | PDK2 (0.61) | PDK2PDK4PDK1PDK3CNR1 | |
| SCHEMBL23835843 | 0.78 | CNR1 (0.49) | PDK2PDK4PDK1PDK3CNR1 | |
| SCHEMBL24029211 | 0.78 | CNR1 (0.49) | PDK2PDK4PDK1PDK3CNR1 | |
| SCHEMBL10470225 | 0.77 | PDK2 (0.59) | PDK2PDK4PDK1PDK3CNR1 | |
| SCHEMBL14516941 | 0.76 | PDE7A (0.39) | PDK2PDK4PDK1PDK3CNR1 | |
| SCHEMBL10828347 | 0.76 | PDK2 (0.57) | PDK2PDK4PDK1PDK3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-22 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-0780388-B1 | 5HT1Dalpha and 5HT2A ligands | LILLY CO ELI (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-6166040-A | Indole compounds | ELI LILLY AND COMPANY LIMITED (GB) | 2000-12-26 | — | — | US | disclosed |
| EP-0963983-A1 | Indol-2-ones as serotonin modulators | ELI LILLY AND COMPANY LIMITED (GB) | 1999-12-15 | — | — | EP | disclosed |
| EP-0653426-B1 | Indole derivatives, salts thereof and heart affection therapeutic agent comprising the same | KOWA CO (JP) | 1998-07-22 | — | — | EP | disclosed |
| US-5773448-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-06-30 | — | — | US | disclosed |
| EP-0780388-A1 | 5HT1Dalpha and 5HT2A ligands | LILLY INDUSTRIES LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
| US-5510366-A | INOTROPIC, ANTIARRHYMTHMIA AGENTS, VASODILATORS | KOWA CO., LTD. (JP) | 1996-04-23 | — | — | US | disclosed |
| EP-0653426-A1 | Indole derivatives, salts thereof and heart affection therapeutic agent comprising the same | KOWA COMPANY, LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| US-4933336-A | Thiadiazinone, oxadiazinone and triazinone derivatives, and their use for treating acute or chronic heart disease | LABORATOIRES SOBIO S.A. (FR) | 1990-06-12 | — | — | US | disclosed |
| EP-0303418-A2 | Substituted indolones, useful in the treatment of heart or asthmatic diseases | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | PDK2 321/4885PDK4 235/4885PDK1 504/4885 |
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | PDK2 1714/4885PDK4 2777/4885PDK1 1538/4885 |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, CRH | PDK2 2556/4885PDK4 2817/4885PDK1 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.